#Japan #Tokyo #Hemophilia #CSL Behring #RARE LiNK PROJECT

CSL Behring's Commitment to Awareness for World Hemophilia Day

CSL Behring, a leading global company in the hemophilia space, is gearing up for World Hemophilia Day, which takes place on April 17. The company aims to enhance understanding of hemophilia through continuous educational efforts. This year, they are focusing on two primary activities designed to foster awareness about shared decision-making in treatment.

Concept: 'Draw Your Voice'

Under the campaign theme 'Draw Your Voice,' CSL Behring has organized a workshop where patients, their families, and healthcare providers can come together. The goal is to engage in discussions about the daily life of those living with hemophilia, the collaborative approach to treatment, and their aspirations for the future.

During this gathering, participants' perspectives were visually documented through graphic recording, illustrating how effective communication with healthcare professionals can help patients achieve their goals. The completed graphics and a related video have been released to amplify the importance of Shared Decision-Making (SDM), which emphasizes involving patients in the decision-making process with the support of healthcare providers. More information can be found on their dedicated SDM overview page.

You can view the graphics and the video of this engaging session here.

RARE LiNK PROJECT: Amplifying Voices

Alongside this initiative, CSL Behring is also promoting its RARE LiNK PROJECT, which focuses on raising awareness about rare diseases. In alignment with World Hemophilia Day, the company has published an interview and video featuring Naotaka Sakaguchi, the Youth Hemophilia Club representative and a board member of the Osaka Hemophilia Friends Association.

This content provides insights into the daily lives of those with hemophilia, how they manage treatment, engage with family and healthcare professionals, and set personal goals. This firsthand account highlights the lived experiences of patients and contributes to broader societal understanding. You can watch the video on the RARE LiNK PROJECT site.

Through these activities, CSL Behring is dedicated to supporting individuals with hemophilia in their journey to create a future that reflects their uniqueness while continuing to contribute to the advancement of understanding and treatment in the realm of rare diseases.

About World Hemophilia Day

Established by the World Federation of Hemophilia, this international day aims to increase awareness and improve treatment for hemophilia and other hereditary bleeding disorders. The theme for World Hemophilia Day 2026 is 'Diagnosis: First step to care.' For more specific information, visit the official World Hemophilia Day website.

Understanding RARE LiNK PROJECT

The RARE LiNK PROJECT seeks to connect the voices of patients, families, and healthcare professionals dealing with rare diseases to promote recognition and understanding, aiming to create better support environments. More details can be found on the project site here.

About CSL Behring

CSL Behring is a global biotechnology company specializing in biological medicines for serious and rare diseases. Its mission is to deliver innovative therapies to patients worldwide. In Japan, the company focuses on fields including immune and rare diseases, hereditary angioedema (HAE), hemophilia, and emergency clinical care. For more information, you can visit their official page at CSL Behring Japan.

About CSL Limited

CSL Limited (ASX: CSL, USOTC: CSLLY) boasts a diverse portfolio of life-saving medicines, including treatments for hemophilia and immune deficiencies, influenza preventive vaccines, and therapies for iron deficiency and kidney disease. Established in 1916, the company has leveraged modern technology for over a century to fulfill its promise of saving lives. With approximately 29,000 employees across three divisions—CSL Behring, CSL Seqirus, and CSL Vifor—they serve patients in over 100 countries. For articles on the future of biotechnology, please refer to CSL Behring Vita. Additional information is available at CSL's official website.